Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.

Journal of neuropathology and experimental neurology - 1 May 2026

Higa Nayuta, Akahane Toshiaki, Yokoyama Seiya, Yonezawa Hajime, Makino Ryutaro, Uchida Hiroyuki, Takajo Tomoko, Kirishima Mari, Otsuji Ryosuke, Fujioka Yutaka, Hatae Ryusuke, Kuga Daisuke, Nagasaka Shohei, Suzuki Kohei, Yamamoto Junkoh, Yoshimoto Koji, Tanimoto Akihide, Hanaya Ryosuke

Abstract excerpt

CDKN2A/B homozygous deletion (HD) defines isocitrate dehydrogenase (IDH)-mutant astrocytomas as World Health Organization (WHO) grade 4 and predicts aggressive tumor behavior. To identify clinical and molecular prognostic factors in these tumors, we conducted a retrospective multi-institutional study of 106 adult patients diagnosed with IDH-mutant astrocytomas (21 grade 2, 40 grade 3 and 45 grade 4). Tumors were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Brain Neoplasms

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Share to Young Adult

Source

Identifiers

PMID: 41689537
DOI: 10.1093/jnen/nlaf154

Genes

CDKN2A
MET
PDGFRA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical prognostic factors in isocitrate dehydrogenase-mutant astrocytomas: Insights into biomarker-driven stratification.PMID 41689537Read ↗

Expanding the molecular grading criteria in IDH-mutant astrocytoma.Semantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

Molecular markers related to patient outcome in patients with IDH-mutant astrocytomas grade 2 to 4: A systematic review.Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Refinement of prognostication for IDH-mutant astrocytomas using DNA methylation-based classification.Semantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

DNA copy number patterns reveal prognostic markers and elucidate mechanisms of evolution in IDH-mutant astrocytoma.Semantic proximity Read ↗

Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

CDKN2A mutations have equivalent prognostic significance to homozygous deletion in IDH-mutant astrocytoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.